John William Larson Net Worth

The estimated Net Worth of John William Larson is at least $5.81 Million dollars as of 28 November 2017. John Larson owns over 30,500 units of Sangamo Therapeutics Inc stock worth over $53,491 and over the last 20 years John sold SGMO stock worth over $5,757,315.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

John Larson SGMO stock SEC Form 4 insiders trading

John has made over 55 trades of the Sangamo Therapeutics Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently John exercised 30,500 units of SGMO stock worth $179,645 on 28 November 2017.

The largest trade John's ever made was exercising 49,250 units of Sangamo Therapeutics Inc stock on 11 May 2016 worth over $599,373. On average, John trades about 6,638 units every 65 days since 2004. As of 28 November 2017 John still owns at least 63,680 units of Sangamo Therapeutics Inc stock.

You can see the complete history of John Larson stock trades at the bottom of the page.

What's John Larson's mailing address?

John's mailing address filed with the SEC is C/O SANGAMO BIOSCIENCES IN STE.A-100, POINT RICHMOND TECH CENTER 501 CANA BLVD, RICHMOND, CA, 94804.

Insiders trading at Sangamo Therapeutics Inc

Over the last 24 years, insiders at Sangamo Therapeutics Inc have traded over $87,969,621 worth of Sangamo Therapeutics Inc stock and bought 3,434,008 units worth $48,483,268 . The most active insiders traders include Capital Management, L.P.Ra ..., Le Roy C Kopp, and Inc.Biogen Ma Inc. Biogen. On average, Sangamo Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $40,671. The most recent stock trade was executed by Inc.Biogen Ma Inc. Biogen on 26 September 2023, trading 6,000,000 units of SGMO stock currently worth $3,000,000.

What does Sangamo Therapeutics Inc do?

for sangamo therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. to learn more about sangamo, visit the our website at www.sangamo.com.

Complete history of John Larson stock trades at Sangamo Therapeutics Inc

Sangamo Therapeutics Inc executives and stock owners

Sangamo Therapeutics Inc executives and other stock owners filed with the SEC include:

• Alexander Macrae,
  President, Chief Executive Officer, Director
• Sung Lee,
  Chief Financial Officer, Executive Vice President
• Gary Loeb,
  Executive Vice President, Chief Compliance Officer, General Counsel, Secretary
• Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.,
  CEO, Pres & Director
• R. Andrew Ramelmeier,
  Executive Vice President - Technical Operations
• Dr. R. Andrew Ramelmeier Ph.D.,
  Exec. VP of Technical Operations
• D. Mark McClung,
  Exec. VP & COO
• James Meyers,
  Independent Director
• H. Stewart Parker,
  Independent Director
• Joseph Zakrzewski,
  Independent Director
• Robert Carey,
  Independent Director
• Saira Ramasastry,
  Independent Director
• Karen Smith,
  Independent Director
• McDavid Stilwell,
  IR Contact Officer
• John Markels,
  Independent Director
• Kenneth Hillan,
  Director
• Prathyusha Duraibabu,
  Vice President - Finance
• D. Mark McClung,
  Executive Vice President, Chief Business Officer
• Scott B. Willoughby,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Prathyusha Duraibabu CPA, M.B.A.,
  Sr. VP, CFO & Principal Accounting Officer
• Dr. Jason D. Fontenot Ph.D.,
  Sr. VP & Chief Scientific Officer
• Prathyusha Duraibabu,
  VP of Fin., Principal Accounting Officer & Principal Financial Officer
• Dr. Duncan McKay,
  Sr. VP & GM of Europe
• Heather Erickson,
  Chief of Staff
• Dr. Nathalie Dubois-Stringfellow,
  Sr. VP of Product Devel. & Management
• Whitney Jones,
  Sr. VP & Chief People Officer
• Aron Feingold,
  Head of Corp. Communications & Investor Relations Officer
• Dr. Jason Fontenot Ph.D.,
  Sr. VP & Chief Scientific Officer
• Stephen George Dilly,
  Director
• Paul B Cleveland,
  Director
• Henry Ward Wolff,
  Director
• Steven J Mento,
  Director
• William R Ringo,
  Director
• Geoffrey Nichol,
  Executive Vice President, R&D
• Curt A. Iii Herberts,
  Sr.VP & Chief Business Officer
• Dale G Ando,
  VP, Therapeutic Dev. & CMO
• Edward R. Conner,
  Sr. VP & Chief Medical Officer
• Thomas G Wiggans,
  Director
• William G Gerber,
  Director
• Roger Jeffs,
  Director
• Heather D Turner,
  EVP, General Counsel & Sec.
• Robert J. Schott,
  SVP, Head of Development
• Stephane Boissel,
  EVP, Corp. Strategy
• Kathy Yi,
  EVP & Chief Financial Officer
• Margaret Liu,
  Director
• Michael C Wood,
  Director
• Greg Zante,
  Sr Dir., Finance and Admin
• Le Roy C Kopp,
  10% owner
• Edward O Ii Lanphier,
  President and CEO
• Jon E M Jacoby,
  Director
• Casey C Case,
  Vice President, Research
• Peter Bluford,
  V.P., Corporate Development
• William J Rutter,
  Director
• John William Larson,
  Director
• Philip D Gregory,
  Vice President, Research
• Capital Management, L.P.Ra ...,
  
• David G Ichikawa,
  Senior VP, Bus. Dev.
• Jason D. Fontenot,
  SVP, Chief Scientific Officer
• Scott B. Willoughby,
  SVP, GEN. COUNSEL & SECRETARY
• Inc.Biogen Ma Inc. Biogen,
  
• Sandy Macrae,
  PRESIDENT, CEO AND DIRECTOR
• Nathalie Dubois Stringfellow,
  SVP-CHIEF DEVELOPMENT OFFICER
• Amy Pooler,
  VP, HEAD OF RESEARCH
• Courtney Beers,
  
• Margaret A Horn,